BIIB Chart

1 Month

	Date	Diff	Articles
	2025-05-02	+2.15 %	Biogen (BIIB) stock rose by 2.15% due to the positive outlook and a new price target of $199.00 set by Truist Financial, indicating analyst confidence in the company's future performance.
Biogen (BIIB) stock rose by 2.15% due to the positive outlook and a new price target of $199.00 set by Truist Financial, indicating analyst confidence in the company's future performance. Biogen's (NASDAQ: BIIB) stock rose 2.15% following the release of its quarterly earnings report, which, despite missing earnings estimates, revealed higher-than-expected revenue growth, leading to increased investor interest and a positive market response. Biogen (BIIB) stock rose 2.15% following a positive price target adjustment by Truist Financial, which increased its price target to $199.00, indicating investor confidence in the company's prospects. Biogen (NASDAQ:BIIB) stock rose 2.15% despite a decrease in target prices from several analysts, possibly due to stronger-than-expected quarterly revenue of $2.43 billion, which exceeded analysts' estimates.
	2025-05-01	-0.12 %	Biogen stock has experienced a slight decline of 0.12% despite beating first-quarter expectations and reporting strong sales for its new drugs, Leqembi and Skyclarys, likely due to market volatility or profit-taking after the positive earnings report.
Biogen stock has experienced a slight decline of 0.12% despite beating first-quarter expectations and reporting strong sales for its new drugs, Leqembi and Skyclarys, likely due to market volatility or profit-taking after the positive earnings report.
	2025-04-30	+0.76 %	Biogen (NASDAQ:BIIB) stock rose by 0.76% despite being downgraded from "strong-buy" to "hold" by HSBC Global Research, as well as facing price target reductions from several analysts, possibly due to its solid earnings performance and ongoing interest from institutional investors.
Biogen (NASDAQ:BIIB) stock rose by 0.76% despite being downgraded from "strong-buy" to "hold" by HSBC Global Research, as well as facing price target reductions from several analysts, possibly due to its solid earnings performance and ongoing interest from institutional investors.
	2025-04-29	+0.88 %	Biogen (NASDAQ:BIIB) stock rose 0.88% in response to positive market sentiment ahead of its anticipated Q1 2025 earnings report, where analysts expect it to exceed earnings expectations.
Biogen (NASDAQ:BIIB) stock rose 0.88% in response to positive market sentiment ahead of its anticipated Q1 2025 earnings report, where analysts expect it to exceed earnings expectations. Biogen Inc. (BIIB) shares rose by 0.88% despite a downgrade in Q2 earnings estimates by investment analysts, reflecting investor confidence in the company following its recent quarterly earnings beat and ongoing interest from institutional investors.
	2025-04-25	-0.56 %	Biogen (NASDAQ:BIIB) stock declined by 0.56% after The Goldman Sachs Group lowered its price target for the company from $219.00 to $197.00, which contributed to negative market sentiment despite maintaining a "buy" rating.
Biogen (NASDAQ:BIIB) stock declined by 0.56% after The Goldman Sachs Group lowered its price target for the company from $219.00 to $197.00, which contributed to negative market sentiment despite maintaining a "buy" rating.
	2025-04-23	-0.61 %	Biogen (NASDAQ:BIIB) stock decreased by 0.61% following various downgrades and price target reductions by multiple investment analysts, although Royal Bank of Canada raised its price objective for the stock.
Biogen (NASDAQ:BIIB) stock decreased by 0.61% following various downgrades and price target reductions by multiple investment analysts, although Royal Bank of Canada raised its price objective for the stock. Biogen (BIIB) stock declined by 0.61% as investors remain cautious about the future profitability of biotech firms, particularly in light of expected patent expirations affecting major players in the industry, including Biogen.
	2025-04-21	-1.79 %	The article compares Sangamo Therapeutics and Vericel in terms of their financial performance and investment potential, indicating that Biogen's stock (BIIB) is down by -1.79% possibly due to investor concerns affecting related biotech stocks, although specific reasons for Biogen's decline were not mentioned.
The article compares Sangamo Therapeutics and Vericel in terms of their financial performance and investment potential, indicating that Biogen's stock (BIIB) is down by -1.79% possibly due to investor concerns affecting related biotech stocks, although specific reasons for Biogen's decline were not mentioned.
	2025-04-17	+2.88 %	Biogen Inc. (NASDAQ:BIIB) saw its stock rise by 2.88% following reduced earnings estimates from analysts at Leerink Partners, despite their ongoing challenges highlighted by various analysts lowering target prices and ratings.
Biogen Inc. (NASDAQ:BIIB) saw its stock rise by 2.88% following reduced earnings estimates from analysts at Leerink Partners, despite their ongoing challenges highlighted by various analysts lowering target prices and ratings.
	2025-04-10	-5.9 %	Biogen (BIIB) stock declined by 5.9% due to negative developments at its collaborative partner Sage Therapeutics, which have led to investor concerns regarding the approval status and efficacy of their key drug zuranolone, along with the abandonment of other drug developments, prompting a securities fraud investigation.
Biogen (BIIB) stock declined by 5.9% due to negative developments at its collaborative partner Sage Therapeutics, which have led to investor concerns regarding the approval status and efficacy of their key drug zuranolone, along with the abandonment of other drug developments, prompting a securities fraud investigation.
	2025-04-08	-4.31 %	Biogen Inc. (NASDAQ:BIIB) stock dropped by 4.31%, with analysts primarily maintaining a "Hold" consensus rating and recent downgrades on price targets, which may have contributed to the decline.
Biogen Inc. (NASDAQ:BIIB) stock dropped by 4.31%, with analysts primarily maintaining a "Hold" consensus rating and recent downgrades on price targets, which may have contributed to the decline.